UnitedHealth Group Covers Guardant Health's Shield Colorectal Cancer Test

As colorectal cancer rates rise among adults under 50, non-invasive screening methods are gaining attention. According to reports, Guardant Health announced that UnitedHealth Group has become the first major commercial insurer to cover the Shield blood test for colorectal cancer screening for eligible members aged 45 or older.

This decision follows the Shield test receiving necessary regulatory approvals. Market data shows Guardant Health shares closed at $150.03 on June 30, 2026, up from a session low of $148.29. Colorectal cancer is the second deadliest cancer in the US, with rising incidence among younger age groups.

At the June 30 close, GH stock reached a high of $152.72 intraday, indicating upward momentum. The market will likely focus on any future announcements of additional insurer coverage for the Shield test, which could expand market access. Additionally, further clinical trial results or competition from other tests may influence the stock's trajectory.